Article Information
History
- July 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Geoffrey S. Dow*,1,
- Angela Luttick2,
- Jen Fenner2,
- David Wesche3,
- Karen Rowland Yeo4 and
- Craig Rayner3,5
- 160 Degrees Pharmaceuticals LLC, 1025 Connecticut Ave NW, Suite 1000, Washington DC, 20036, United States
- 2360Biolabs, 85 Commercial Road, Melbourne, Victoria, 3004, Australia
- 3Certara, 100 Overlook Center #101, Princeton, NJ, 08540
- 4Certara UK Limited (Simcyp Division), Level 2, Acero, 1 Concourse Way, Sheffield S1 2BJ, UK
- 5Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, VIC Australia
- ↵*Corresponding author: inquiries{at}60-p.com
Posted July 12, 2020.
Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro
